Multicenter Longitudinal Observational Study Pharmaceuticals Alflutop in Russia (message 2)
暂无分享,去创建一个
A. Lila | L. Alekseeva | N. Kashevarova | E. Taskina | Лила А.М | Таскина Е.А | Алексеева Л.И | Кашеварова Н.Г
[1] L. Vasilyeva,et al. The role of chondroprotectors in the correction of pain in patients with osteoarthritis of the joints of the hands with Heberden’s nodes , 2022, Pharmateca.
[2] Peng Cheng,et al. Epidemiological trends of hand osteoarthritis from 1990 to 2019: Estimates from the 2019 Global Burden of Disease study , 2022, Frontiers in Medicine.
[3] I. Ackerman,et al. Global Burden of Disease Study 2019: an opportunity to understand the growing prevalence and impact of hip, knee, hand and other osteoarthritis in Australia , 2022, Internal medicine journal.
[4] Qiang Liu,et al. Prevalence Trends of Site‐Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019 , 2022, Arthritis & rheumatology.
[5] A. Karateev. Bioactive concentrate from small sea fish: evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials , 2020 .
[6] V. Mazurov,et al. A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop® in an alternating dosing regimen versus the standard one. Communication 2: Evaluation of the efficacy of the drug in different use regimens , 2020, Modern Rheumatology Journal.
[7] G. Guyatt,et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee , 2020, Arthritis care & research.
[8] J H Abbott,et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. , 2019, Osteoarthritis and cartilage.
[9] J. Jordan,et al. Defining multiple joint osteoarthritis, its frequency and impact in a community-based cohort. , 2019, Seminars in arthritis and rheumatism.
[10] E. Taskina,et al. Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment , 2019, Modern Rheumatology Journal.
[11] Наталья Гаврииловна Кашеварова,et al. Остеоартрит: эпидемиология, классификация, факторы риска и прогрессирования, клиника, диагностика, лечение , 2019 .
[12] А. Е. Филатова,et al. Антикоагулянтная терапия и компоненты метаболического синдрома у пациентов с фибрилляцией предсердий в реальной амбулаторной клинической практике , 2019 .
[13] Л. И. Алексеева,et al. Многоцентровое слепое рандомизированное плацебоконтролируемое исследование симптом- и структурно-модифицирующего действия препарата алфлутоп у больных остеоартрозом коленных суставов. Сообщение 2 – оценка структурно- модифицирующего действия препарата , 2014, RSP 2014.
[14] J. Jordan,et al. "Generalized osteoarthritis": a systematic review. , 2014, Seminars in arthritis and rheumatism.
[15] N. Shostak,et al. MULTICENTER DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE SYMPTOM- AND STRUCTURE-MODIFYING EFFECT OF ALFLUTOP IN PATIENTS WITH KNEE OSTEOARTHROSIS. COMMUNICATION 1. EVALUATION OF THE SYMPTOM-MODIFYING EFFECT OF THE DRUG , 2013 .
[16] P. Croft,et al. Defining and mapping the person with osteoarthritis for population studies and public health , 2013, Rheumatology.
[17] J A Sigidin,et al. Алфлутоп в терапии остеоартроза , 2004 .
[18] Hyoung-Woo Lee,et al. Diagnosis and treatment of metabolic syndrome , 2006 .